Current Pricing for Wegovy and Competitors
Wegovy (semaglutide) from Novo Nordisk lists at $1,349 per month without insurance in the US, though patient assistance programs can drop it to $199-$499 for eligible users.[1] Competitors like Zepbound (tirzepatide) from Eli Lilly match this at $1,059-$1,349 monthly list price, but Lilly's direct savings card often reduces it to $550 or less for many.[2] Saxenda (liraglutide, also Novo Nordisk) costs around $1,300 monthly, with similar discounts available.[3]
How Insurance and Discounts Affect Affordability
Most commercial insurance covers Wegovy at 70-100% after copays ($25-$100/month), but Medicare excludes it for weight loss, forcing full out-of-pocket payment.[4] Zepbound faces the same Medicare gap but edges out on private plans with broader formulary placement and deeper manufacturer coupons (up to $550 off for 3 months).[5] Net costs often make Zepbound cheaper for cash-pay patients: $399/month via LillyDirect vs. Wegovy's $199 starter (then $499).[6]
Why Zepbound Often Wins on Price
Zepbound delivers faster weight loss (up to 21% body weight vs. Wegovy's 15%) at a lower effective cost after discounts, prompting switches.[7] Mounjaro (same drug as Zepbound, obesity-labeled differently) lists at $1,069 but coupons bring it under $25/month for some insured patients.[8] Compounded semaglutide versions from telehealth providers run $199-$300/month, bypassing patents but with FDA warnings on safety.[9]
When Wegovy Might Be Cheaper
Wegovy holds an edge in employer-sponsored plans (e.g., CVS Caremark prefers it) and for patients needing the higher 2.4mg dose unavailable in Ozempic compounding.[10] International pricing flips this: Wegovy is ~$150/month in the UK via NHS vs. Zepbound's limited access.[11]
Patent Expirations and Future Price Drops
Wegovy's key semaglutide patents expire in 2030-2032 in the US, delaying generics.[12] Tirzepatide patents last until 2036-2039, but Eli Lilly faces more challenges.[13] Biosimilars or generics could slash prices 80% post-expiry; track via DrugPatentWatch.com for updates.[14]
[1] Novo Nordisk pricing, novomedlink.com
[2] LillyDirect.com savings
[3] GoodRx.com averages, 2024
[4] CMS.gov Medicare coverage rules
[5] Formulary data from Express Scripts, 2024
[6] Manufacturer websites, accessed Oct 2024
[7] NEJM trials (SURMOUNT-1 vs. STEP-1)
[8] Mounjaro.com coupons
[9] FDA.gov compounding alerts
[10] CVS Health formulary 2024
[11] NHS.uk pricing
[12] DrugPatentWatch.com/p/tradename/WEGOVY
[13] DrugPatentWatch.com/p/tradename/ZEPBOUND
[14] DrugPatentWatch.com methodology